Efficacy and Safety of SGLT2 inhibitors in patients with type 1 diabete.
Not Applicable
Recruiting
- Conditions
- type 1 diabetes
- Registration Number
- JPRN-UMIN000044317
- Lead Sponsor
- Hokkaido University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who were thought to be inappropriate to enter this study for some reasons by physician's judgments
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How do SGLT2 inhibitors modulate glucosuria and ketogenesis in type 1 diabetes patients (JPRN-UMIN000044317)?
What is the comparative effectiveness of SGLT2 inhibitors versus standard insulin therapy in T1DM glycemic control?
Which biomarkers predict response to SGLT2 inhibitors in type 1 diabetes observational studies (Hokkaido University Hospital)?
What are the potential adverse events of SGLT2 inhibitors in T1DM patients and management strategies (JPRN-UMIN000044317)?
How do SGLT2 inhibitors like dapagliflozin compare with GLP-1 agonists in managing type 1 diabetes complications (Hokkaido University Hospital trial)?